Salarius Pharmaceuticals, Inc.

Clinical-stage biopharma developing targeted protein therapies for cancer and viral diseases.

SLRX | NDAQ

Overview

Corporate Details

ISIN(s):: US79400X4043 (+1 more)
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://salariuspharma.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cancer and other diseases with high unmet medical needs. The company's technology aims to correct the dysregulated gene expression that drives disease progression. Its pipeline is built on two primary drug classes: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials for solid and hematologic cancers like leukemias and lymphomas. The company's TPD candidate, SP-3164, is in IND-enabling studies. Following a merger with Decoy Therapeutics, Salarius is also advancing peptide therapeutics for cancer and respiratory viruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Salarius Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Salarius Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Salarius Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Hybrigenics SA R&D provider of molecular interaction analysis to accelerate drug discovery for life science sectors.	France	ALHYG
Hyundai ADM Bio lnc. Korean CRO offering end-to-end clinical trial services for pharma & bio ventures.	South Korea	187660
HYUNDAI BIOSCIENCE CO., LTD. Clinical-stage biotech developing safer antiviral & anticancer drugs via advanced drug delivery systems.	South Korea	048410
iBio, Inc. AI-powered biotech developing antibody therapeutics for cardiometabolic diseases and obesity.	United States of America	IBIO
Ibotta, Inc. A performance marketing platform offering cash-back rewards to consumers from CPG brands.	United States of America	IBTA
ICON PLC Global CRO providing outsourced development & commercialization for pharma, biotech & device firms.	United States of America	ICLR
IDEAYA Biosciences, Inc. Clinical-stage firm developing precision cancer therapies via synthetic lethality.	United States of America	IDYA
IMGT Corporation Limited Develops a drug delivery platform using ultrasound and nanotech for oncology.	South Korea	456570
IMMERSION CORP Licenses patented haptic feedback technology for mobile, gaming, and automotive interfaces.	United States of America	IMMR
IMMUNIC, INC. Developing oral small molecule therapies for chronic inflammatory and autoimmune diseases.	United States of America	IMUX